|
1925 |
Established Takara Shuzo Co., Ltd |
|
1970 |
Launched the Central Research Laboratories in the city of Otsu, Shiga |
|
1973 |
Developed and commercialized an artificial cultivation method for Bunashimeji mushrooms |
|
1979 |
Commenced sales of the first domestically produced restriction enzymes as reagents for genetic engineering research Entered Biomedical Business |
|
1988 |
Acquired exclusive distribution rights in Japan for a gene amplification system using PCR technology |
|
1993 |
Obtained worldwide PCR-related patent licenses to manufacture PCR products |
|
1993 |
Established Takara Biotechnology (Dalian) Co., Ltd. in China, in order to manufacture life science research reagents |
|
1995 |
Established Takara Biomedical Europe S.A.(currently Takara Bio Europe S.A.S) in Paris, France, in order to sell life science research reagents |
|
1995 |
Developed the RetroNectin® Method for highly-efficient retrovial transduction in hematopoietic stem cells |
|
1995 |
Established Bohan Biomedical Inc.(currently Takara Korea Biomedical Inc.) in Seoul, Korea |
|
2000 |
Established DRAGON GENOMICS Co., LTD. (merged to Takara Bio in 2002) Launched full-scale genetic analysis services |
|
2001 |
Established Mizuho Norin Co., Ltd. (transferred to YUKIGUNI MAITAKE CO., LTD. in 2019) |
|
2002 |
Established Takara Bio Inc. in the city of Otsu, Shiga, split off from Takara Shuzo, Co., Ltd. |
|
2004 |
Established Takara Biomedical Technology (Beijing) Co., Ltd. in China |
|
2004 |
Listed on the TSE Mothers Index |
|
2005 |
Acquired U.S.-based Clontech Laboratories, Inc. (currently Takara Bio USA, Inc.) |
|
2007 |
Established KINOKO CENTER KIN INC. in Okinawa (transferred to YUKIGUNI MAITAKE CO., LTD. in 2019) |
|
2011 |
Established DSS Takara Bio India Pvt. Ltd. in New Delhi, India |
|
2014 |
Acquired Cellectis AB (currently Takara Bio Europe AB) in Göteborg, Sweden |
|
2014 |
Launched the Center for Gene and Cell Processing Started CDMO business providing manufacturing and development support services for regenerative medicine products, etc. |
|
2015 |
Launched new research facility in Kusatsu, Shiga Headquarters functions relocated |
|
2016 |
Changed listing to the First Section of the TSE |
|
2017 |
Acquired Rubicon Genomics, Inc. by wholly-owned subsidiary Takara Bio USA Holdings, Inc., thereafter merged to Takara Bio USA, Inc. |
|
2017 |
Acquired Wafergen Bio-systems, Inc. by wholly-owned subsidiary Takara Bio USA Holdings, Inc., thereafter merged to Takara Bio USA, Inc. |
|
2018 |
Designated NY-ESO-1 siTCR~{TM} as a product under the "SAKIGAKE Designation System". |
|
2019 |
Transferred the AgriBio Business |
|
2020 |
Launched the Center for Gene and Cell Processing II |
|
2020 |
Launched Takara SARS-CoV-2 Direct PCR kit, an in vitro diagnostic |
|
2020 |
NY-ESO-1 siTCR~{TM} designated as an Orphan Regenerative Medicine |
|
2021 |
Established Takara Bio UK Ltd. |
|
2021 |
Takara Bio USA Inc. relocated its headguarters to San Jose, California, USA |
|
2022 |
Changed to the Prime Market of the Tokyo Stock Exchange |
